Obesity – Landscape & Forecast – Disease Landscape & Forecast (G7)

Obesity is a major public health problem; growing evidence underscores its substantial medical and economic impact. The emergence of GLP-1 RAs has spurred substantial demand and market opportunity for safe and effective antiobesity drugs. These agents mimic natural gut hormones that regulate appetite and energy metabolism, delivering weight loss that approaches bariatric surgery. Meanwhile, traditional drug treatments—such as noradrenergic anorectics (phentermine), lipase inhibitors (orlistat), and FDCs (Contrave / Mysimba, Qsymia)—are losing ground as the products of choice. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound / Mounjaro are the leading brands driving rapid market growth. Alongside a promising pipeline of next-generation GLP-1 RAs, these therapies are poised to transform obesity treatment by providing health benefits beyond weight loss. While the high prevalence of the disease is prompting payers to limit access because of budget constraints, the long-term clinical and economic benefits of addressing the obesity epidemic position these therapies as a breakthrough in medicine.

Questions answered

• Which metabolic and central pathways have high potential as drug targets?
• What is the prevalence of obesity in the major pharmaceutical markets under study?
• How is obesity currently treated? What do experts think about Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) as treatments for obesity patients?
• What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
• How will the obesity therapy market evolve over the next 10 years?

Geography

United States, EU5, Japan

Primary research

• Country-specific interviews with thought-leading cardiologists
• Survey data collected for this and other Clarivate research

Epidemiology

Number of obesity and drug-eligible cases by country, including diagnosed and drug-treated populations

Forecast

10-year, annualized, drug-level sales and patient share of key obesity therapies through 2034, segmented by brands / generics

Drug treatments

Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.